



# Il referto istologico dei tumori T1 nella gestione clinica dei pazienti

**Paola Cassoni**



# La diagnosi standardizzata dei T1


**Best practice** nel report istologico:  
la refertazione utile alla gestione del  
paziente deve prevedere l'inclusione di  
tutti i parametri necessari per la scelta  
chirurgia vs non chirurgia



**Alto rischio vs basso rischio**

**I requisiti minimi irrinunciabili  
della refertazione istologica**





## T1 High Risk

C) FRAMMENTI DI ADENOCARCINOMA INIZIALE MODERATAMENTE DIFFERENZIATO (G2), CON AREE DI SCARSA DIFFERENZIAZIONE (G3) DEL GROSSO INTESTINO INSORTO IN ADENOMA TUBULO-VILLOSO (cd ADENOMA CANCERIZZATO) (pT1, sm3).

**Grado istologico:** Moderatamente differenziato (G2) con campi G3

**Profondità di invasione:** Tumore che invade la sottomucosa (pT1)

**Livello di invasione della sottomucosa:** sm3 (Sec. Kikuchi).

**Profondità di invasione della sottomucosa:** > 2 mm.


**Ampiezza di invasione della sottomucosa:** > 4 mm.

**Invasione vascolare ematica o linfatica:** Non evidente sulle sezioni esaminate

**Budding tumorale:** alto grado

**Rapporto quantitativo tessuto adenomatoso/adenocarcinoma:** 60/40

**Margini di resezione:** margine di resezione chirurgica diffusamente infiltrato da adenocarcinoma



# T1 High Risk

**Recidiva:**

- **Margini positivi**

**Metastasi LN:**

- **G3**
- **Invasione vascolare**
- **Ampiezza > 2 mm**

C) FRAMMENTI DI ADENOCARCINOMA INIZIALE MODERATAMENTE DIFFERENZIATO (G2), CON AREE DI SCARSA DIFFERENZIAZIONE (G3) DEL GROSSO INTESTINO INSORTO IN ADENOMA TUBULO-VILLOSO (cd ADENOMA CANCERIZZATO) (pT1, sm3).

**Grado istologico:** Moderatamente differenziato (G2) con campi G3

**Profondità di invasione:** Tumore che invade la sottomucosa (**pT1**)


**Livello di invasione della sottomucosa:** sm3 (Sec. Kikuchi).

**Profondità di invasione della sottomucosa:** > 2 mm.

**Ampiezza di invasione della sottomucosa:** > 4 mm.

**Invasione vascolare ematica o linfatica:** Non evidente sulle sezioni esaminate

**Budding tumorale:** alto grado




# T1 High Risk

**Recidiva:**

- **Margini positivi**

**Metastasi LN:**

- **G3**
- **Invasione vascolare**
- **Ampiezza > 2 mm**
- **Profondità > 4 mm**
- **Budding high grade**



# T1 Low Risk

ADENOCARCINOMA INIZIALE MODERATAMENTE DIFFERENZIATO (G2) DEL GROSSO INTESTINO INSORTO IN ADENOMA TUBULO-VILLOSO (cd ADENOMA CANCERIZZATO) (pT1,sm1).

## Grado istologico

Moderatamente differenziato (G2)

**Crescita:** Infiltrante

**Profondità di invasione:** Tumore che invade la sottomucosa (pT1)

**Livello di invasione della sottomucosa:** sm1 (Sec. Kikuchi).

**Profondità di invasione della sottomucosa:** < 1 mm.


**Ampiezza di invasione della sottomucosa:** < 2 mm.

**Invasione vascolare ematica o linfatica:** Non evidente sulle sezioni esaminate

**Budding tumorale:** basso grado

**Rapporto quantitativo tessuto adenomatoso/adenocarcinoma :** 95/5

**Margini di resezione:** margini di resezione chirurgica -ove valutabile- indenne



## **T1 Low Risk**


- **G1-G2**
- **No invasione vascolare**
- **Ampiezza < 2mm**
- **Profondità < 4 mm**
- **Budding low grade**
- **Margini indenni**

Review

# Management of colorectal T1 carcinoma treated by endoscopic resection

Yusuke Saitoh,<sup>1</sup> Yuhei Inaba,<sup>1</sup> Takahiro Sasaki,<sup>1</sup> Ryuji Sugiyama,<sup>1</sup> Ryuji Sukegawa<sup>1</sup> and Mikihiro Fujiya<sup>2</sup>

<sup>1</sup>Digestive Disease Center, Asahikawa City Hospital, and <sup>2</sup>Division of Gastroenterology and Hematology/Oncology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan



**Figure 2** Therapeutic strategy for submucosal (T1) carcinomas after endoscopic resection based on Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines for the Treatment of Colorectal Cancer 2014.

## Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer

**C. Beaton\***, **C. P. Twine\***, **G. L. Williams\*** and **A. G. Radcliffe†**

\*Department of Colorectal Surgery, Royal Gwent Hospital, Newport, UK and †Screening Division, Public Health Wales, Cardiff, UK

Received 18 June 2012; accepted 4 September 2012; Accepted Article online 20 January 2013

Twenty-three cohort studies including  
**4510** patients were analysed.

# T1 e rischio di metastasi linfonodale

There was a significantly higher risk of LN metastasis with a depth of submucosal invasion  $> 1$  mm than with lesser degrees of penetration (OR 3.87, 95% CI 1.50-10.00,  $P = 0.005$ ).

Lymphovascular invasion was significantly associated with LN metastasis (OR 4.81, 95% CI 3.14-7.37,  $P < 0.00001$ ).

Poorly differentiated tumours had a higher risk of LN metastasis compared with well or moderately differentiated tumours (OR 5.60, 95% CI 2.90-10.82,  $P < 0.00001$ ).

Tumour budding was found to be significantly associated with LN metastasis (OR 7.74, 95% CI 4.47-13.39,  $P < 0.001$ ).

CLINICAL GUIDELINES


## **Practice parameters for early colon cancer management: Italian Society of Colorectal Surgery (Società Italiana di Chirurgia Colo-Rettale; SICCR) guidelines**

**F. Bianco<sup>1</sup> · A. Arezzo<sup>2</sup> · F. Agresta<sup>3</sup> · C. Coco<sup>4</sup> · R. Faletti<sup>5</sup> · Z. Krivocapic<sup>6</sup> ·  
G. Rotondano<sup>7</sup> · G. A. Santoro<sup>8</sup> · N. Vettoretto<sup>9</sup> · S. De Franciscis<sup>1</sup> ·  
A. Belli<sup>1</sup> · G. M. Romano<sup>1</sup>**

# T1 e rischio di metastasi linfonodale


- The potential risk of lymph node metastasis ranges from **6 to 19 %**
- **Profondità di invasione:** risk of lymph node metastasis ranges from 1 % in sm1 to up to 15 % in sm3 lesions
- submucosal depth of invasion between 1 and 2 mm risk: 1.3 to 4 %; 12–18 % of patients with submucosal invasion depth >2 mm
- submucosal invasion depth <1 mm: risk of LN metastases not zero (1.9 %), if >1 mm 14.6 %

Da dove si misura?



## Practical problems of measuring depth of submucosal invasion in T1 colorectal carcinomas

Yuta Kouyama<sup>1</sup> · Shin-ei Kudo<sup>1</sup> · Hideyuki Miyachi<sup>1</sup> · Katsuro Ichimasa<sup>1</sup> · Tomokazu Hisayuki<sup>1</sup> · Hiromasa Oikawa<sup>1</sup> · Shingo Matsudaira<sup>1</sup> · Yui J. Kimura<sup>1</sup> · Masashi Misawa<sup>1</sup> · Yuichi Mori<sup>1</sup> · Kenta Kodama<sup>1</sup> · Toyoki Kudo<sup>1</sup> · Takemasa Hayashi<sup>1</sup> · Kunihiro Wakamura<sup>1</sup> · Atsushi Katagiri<sup>1</sup> · Eiji Hidaka<sup>1</sup> · Fumio Ishida<sup>1</sup> · Shigeharu Hamatani<sup>1,2</sup>





**B**





Fig. 5 A case in which determining the submucosal invasion depth measurement baseline was difficult. a A 23-mm non-granular LST located in the ascending colon. b The pathological finding of desmin antibody staining. The submucosal invasion depth was 630  $\mu\text{m}$  when measured from the lower line (Fig. 5b, a), 1325  $\mu\text{m}$  when measured from the upper line (Fig. 5b, b), and 2150  $\mu\text{m}$  when measured from the surface of the lesion (Fig. 5b, c)

# T1 e rischio di metastasi linfonodale

- **Invasione vascolare:** Fattore di rischio indipendente confermato in più studi con >200 pT1 valutati



- **Budding tumorale:** dimostrata associazione con HR ma spesso coesistente ad altri fattori avversi (i.e. G3)




# T1 e rischio di metastasi linfonodale

- **Poor differentiation:** found in a small proportion of colorectal malignant polyp, with a rate ranging between 4 and 7.2 %

Poorly differentiated clusters :PDCs

# T1 e rischio di metastasi linfonodale


J Gastroenterol (2014) 49:1314–1323  
DOI 10.1007/s00535-013-0881-3



ORIGINAL ARTICLE—ALIMENTARY TRACT

## Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review

Hideki Ueno · Kazuo Hase ·  
Shin-ei Kudo · Masafumi Ta  
Keiji Matsuda · Koji Komor  
Eiji Shinto · Takahiro Nakai



Poorly differentiated clusters :PDCs

**Table 2** Correlation between poorly differentiated clusters and other histopathological characteristics in early invasive colorectal cancer

	Poorly differentiated cluster		<i>P</i> value
	Negative	Positive (%)	
Depth of submucosal invasion			
<1000 $\mu\text{m}$	434	94 (17.8)	<0.0001
$\geq 1000 \mu\text{m}$	1721	1307 (43.2)	
Tumor grade			
Grade 1	1784	862 (32.6)	<0.0001
Grade 2	348	496 (58.8)	
Grade 3	23	43 (65.2)	
Vascular invasion			
Negative	1489	688 (31.6)	<0.0001
Positive	666	713 (51.7)	
Tumor budding			
Low grade	2022	955 (32.1)	<0.0001
High grade	133	446 (77.0)	

Comparison of risk factors in terms of their ability to identify the risk of LNM.

REVIEW

## **Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer**


**Hiroo Wada · Manabu Shiozawa · Kayoko Katayama ·  
Naoyuki Okamoto · Yohei Miyagi · Yasushi Rino ·  
Munetaka Masuda · Makoto Akaike**

### Solo budding e invasione vascolare fattori di rischio indipendenti

- <800 pazienti
- Solo studi giapponesi
- Utilizzo di anticorpi e immunoistochimica

# T1 e rischio di malattia residua

- Margin  $>1$  mm in absence of any other adverse factor: recurrence risk 2 %
- Margin  $>2$  mm leads to a very low possibility of residual disease
- Margin  $<1$  mm similar to involvement both in terms of recurrences/residual disease or lymph node metastases, with a recurrence rate ranging between 21 and 33 %



# LN metastasi: quanti LN tolti?

- In recent population studies conducted in the USA and Europe, it has been reported that the “magic” number of 12 lymph nodes examined is rarely achieved in district or community hospitals which fail to hit the target in 33–60 % of the cases.

# Lo screening nel 2014 in Piemonte

		Piemonte			
		TOTALE			
16432		77	0,47%		
I Esame		CCR			
38345		64	0,17%		
Esami successivi		CCR			
		STADIATI			
				pT1	% pT1
13291		62	38	16	0,12%
I Esame		CCR	61,3%	42,1%	
				pT1	% pT1
23743		45	37	11	0,05%
Esami successivi		CCR	82,2%	29,7%	


# Lo screening nel 2014 in Piemonte

- *Sigmoidoscopia:*

28 CCR su 10471 esami



18 stadiati di cui 7 pT1



- 38,9% dei CCR
- 0.07% sul totale degli esami

# Diagnosi pT1: State of the art

AQ completezza referto:

- 2000-2003 → 65%
- 2008-2012 → 88,9%

*E ora?*

pT1 colon- istologico in *screening*  
*regionale*


Referti completi = 23/28 82%

Referti incompleti = 5/28 18%


# Referti **incompleti** = 5/28

## 18%


*Dati mancanti:*




Invasione vascolare:  $3/5 = 60\%$



Profondità e ampiezza:  $4/5 = 80\%$




Budding:  $3/5 = 60\%$



Margini (valutabili):  $1/5 = 20\%$


# Appropriatezza e ASL

Referti incompleti:  $5/28 = 18\%$



# Appropriatezza del trattamento

RADICALIZZAZIONI:  $14/28 = 50\%$



**Conformi:  $13/14 = 93\%$**


**Non conformi:  $1/14 = 7\%$**



Referto incompleto/ non idoneo alla  
valutazione chirurgica

# Appropriatezza del trattamento

NON RADICALIZZATI:  $14/28 = 50\%$



**Conformi:  $3/14 = 21\%$     Non Conformi :  $11/14 = 79\%$**

$8/11 = 73\%$  UNDERTREATMENT (?)

$3/11 = 27\%$  Referto incompleto/ non idoneo alla valutazione chirurgica

# Distribuzione dei parametri in pT1 HR

- 21HR/23 referti completi (91%)

G3: 13 (62%)

>2mm prof : 9 (43%)(4 in G3)

inv vasc: 2 (9%)(tutti G3, prof >2mm,  
budding hg)

budding hg: 6 (28%) (tutti G3)

margini interessati: 7 (33%)

# Referto istologico radicalizzazioni

- N+: 3/14 (21%)  
2 N1, 1 N2b

Fattori di rischio:

N1: #1,2 profondità e ampiezza

N2b: G3

(tutti casi con margini indenni su polipectomia)

- Tumore presente:  
12/14 (86%),  
1/14 negativo,  
1/14 displasia (margini + su polipectomia)

## Management and short-term outcome of malignant colorectal polyps in the north of England<sup>1</sup>

M. D. Gill\*†, M. D. Rutter†‡§ and S. J. Holtham\*†¶

\*NORCCAG (Northern Colorectal Cancer Audit Group), Wansbeck General Hospital, Northumberland, UK, †NREG (Northern Region Endoscopy Group), UK, ‡University of Durham, Stockton-on-Tees, UK, §Department of Gastroenterology, University Hospital North Tees, Stockton-on-Tees, UK and ¶Department of Surgery, Sunderland Royal Hospital, Sunderland, UK

Received 7 February 2012; accepted 25 April 2012; Accepted Article online 18 June 2012

After initial endoscopic diagnosis, the decision to manage each patient by surgical resection or by endoscopic follow-up alone was made by the MDT. Of the 386 cases, 165 (42.7%) had biopsies taken, with no attempt made to remove the polyp. Of these, all underwent surgery, with 161 (97.6%) resection specimens showing the presence of residual tumour at the site of the biopsy.



# Considerazioni sui dati T1 2014

- La percentuale di N+ nei nostri HR è ai limiti superiori di quanto riportato in letteratura
- Anche in casi in cui i margini erano indenni la radicalizzazione era T+
- Apparente shift verso minore radicalità nel trattamento rispetto al trend passato: MDT?

# Synchronous lymph node metastasis in apparently low-risk T1 colon cancer

*Endoscopy 2014  
Masao et al.*

